by OTC Distribution Drives Tamiflu (Oseltamivir Phosphate) Market
High prevalence of influenza and flu has created a demand for Tamiflu (Oseltamivir Phosphate). Thus, companies are entering into strategic deals to gain rights for over-the-counter (OTC) distribution of the medication. For instance, in July 2019, leading French multinational pharmaceutical company Sanofi entered into an agreement with Roche-a Swiss multinational healthcare company, to gain rights for over-the-counter distribution of Tamiflu in the U.S. Such deals are boosting the growth of the Tamiflu (Oseltamivir Phosphate) market, which is projected to reach a revenue of ~US$ 940 Mn by the end of 2027.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111898
Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing their production capabilities to manufacture novel medication for the prevention and treatment of life-threatening influenza diseases and other flu. They are increasing efficacy in FDA negotiations for marketing and scientific engagement associated with Tamiflu to gain credibility in the global market landscape.
Popularity of OTC Distribution in U.S. Catches Attention of Leading Healthcare Companies
The Tamiflu (Oseltamivir Phosphate) market is witnessing change, since healthcare companies are pervasively switching toward OTC distribution, especially in the U.S. Since the U.S. being one of the rapidly growing economies of North America, the latter is expected to reach the second-highest revenue in the Tamiflu (Oseltamivir Phosphate) market by the end of 2027. Hence, companies in the U.S. are capitalizing on the trend of OTC switch. Looking at leading market players, even emerging players are aiming at the OTC switch and aiming toward strategic transactions to introduce innovations in Tamiflu (Oseltamivir Phosphate).
Companies in the market for Tamiflu (Oseltamivir Phosphate) are targeting the U.S., since the region is one of the largest OTC market worldwide. The OTC switch is supporting the global cough and cold strategy of market players by expanding into flu with a sustainable point of difference in the market. Tamiflu is being highly publicized in support of public health, since novel medication offers safe and efficacious treatment for flu and influenza.
Companies Target Patients with Renal Diseases to Grow in Global Market
Health institutions such as the Centers for Disease Control and Prevention, U.S., recommend that newly born infants should receive flu vaccine at regular periodic intervals. However, frequent replication and mutation of the influenza virus has contributed toward high prevalence of the infection. This phenomena has fueled the demand for Tamiflu (Oseltamivir Phosphate) medication. However, substitute antiviral drugs such as Baloxavir marboxil and Peramivir pose as a threat to the sales of Tamiflu (Oseltamivir Phosphate). Easy availability of substitute drugs explains the steep downward Y-o-Y growth of the Tamiflu (Oseltamivir Phosphate) market. Hence, manufacturers are entering into strategic deals for OTC distribution and increasing production capabilities in dosage forms of Tamiflu.
Get a glimpse of the in-depth analysis through our Report Brochure
Tamiflu capsules dictate the highest revenue as compared to suspension dosages in the Tamiflu (Oseltamivir Phosphate) market and the capsule dosage form segment is predicted for exponential growth in the coming years. On the other hand, companies are increasing the availability of Tamiflu in the suspension dosage form for patients with end-stage renal disease (ESRD) and those on continuous ambulatory peritoneal dialysis (CAPD).
Publicly Funded Research Studies in Europe Offer Strategic Insights to Healthcare Companies
It has been found that Tamiflu (Oseltamivir Phosphate) is an efficacious antiviral drug for the treatment of flu and influenza, especially among the geriatric patients. Companies in the Tamiflu (Oseltamivir Phosphate) market are increasing their focus in Europe, this market in the region is expected for aggressive growth during the forecast period. The Lancet- a European Commission-funded study revealed that Tamiflu (Oseltamivir Phosphate) is recommended by public health agencies for the prevention and treatment of seasonal and pandemic influenza outbreaks.
Ongoing research studies that are publicly funded in several European countries are generating incremental opportunities for companies in the Tamiflu (Oseltamivir Phosphate) market, since companies are gaining important insights through these studies. Healthcare providers in Europe are also recommending Tamiflu for young and old patients with flu-like illnesses.
Analysts’ Viewpoint
Healthcare companies in the Tamiflu (Oseltamivir Phosphate) market are exploring opportunities in Asia Pacific, since government institutions in the region are increasing their efforts to improve the healthcare infrastructure. On the other hand, companies are maximizing their production capabilities to develop generic drugs and increasing efforts to strengthen their online distribution channels.
Tamiflu is efficacious in the treatment of ESRD and for patients who rely on CAPD. However, side effects of Tamiflu, such as diarrhea, and introduction of substitute drugs such as XofluzaTM (baloxavir marboxil) by Roche, are likely to slow down market growth. Hence, companies should increase their efficacy in conducting extensive research studies catering to the development of drugs targeting children and infants.
Tamiflu (Oseltamivir Phosphate) Market: Overview
Tamiflu (Oseltamivir Phosphate) is a medicine under the class of neuraminidase inhibitor used as an antiviral agent
This drug is widely used for the treatment of symptoms caused by the flu virus (Influenza). Tamiflu is a brand name, while oseltamivir phosphate is a generic name for the same. It is available in capsule and oral suspension dosage forms.
Seasonal outbreak of influenza primarily occurs in winter. Most people generally recover fully, but severe complications such as pneumonia can also develop. Initiation of antiviral treatment is recommended for hospitalized influenza patients.
Tamiflu is prescribed for the treatment of acute, and uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. It is also given for prophylactic use as prophylaxis of influenza A and B in patients 1 year and older.
Prevention of flu includes avoiding unnecessary close contact between sick and healthy people, covering mouth and nose while coughing & sneezing, and washing hands frequently
High prevalence, rise in patient population affected by influenza, and pandemic influenza outbreak are some of the major factors responsible for the growth of global Tamiflu (Oseltamivir Phosphate) market
For instance, according to the Centers for Disease Control and Prevention (CDC), around 5% to 20% of the population is affected by the flu in the U.S. each year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the U.S. each year; of these 36,000 die due to flu complications.
Increase in initiatives by regulatory authorities & organizations for treatment and prevention of influenza is also contributing for the growth of the global Tamiflu (Oseltamivir Phosphate) market
Moreover, surge in government funding and measures for influenza treatment & prevention in terms of research activities and awareness campaigns is responsible for the growth of Tamiflu (Oseltamivir Phosphate) market
Market Segmentation: Tamiflu (Oseltamivir Phosphate) Market
Based on drug type, the global Tamiflu (Oseltamivir Phosphate) market has been classified into branded and generic
The generic segment dominated the global Tamiflu (Oseltamivir Phosphate) market in 2018 and its share in global market in increasing
Patent expiry of branded Tamiflu in 2016, several generic products launches, and cheaper products are some of the major factors driving the generic segment
In terms of dosage form, the global Tamiflu (Oseltamivir Phosphate) market has been bifurcated into capsule and suspension
On the basis of Indication, the global market has been segmented into influenza A, influenza B, and others
Based on distribution channel, the global Tamiflu (Oseltamivir Phosphate) market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others
Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights
The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.
Regional Overview: Tamiflu (Oseltamivir Phosphate) Market
In terms of region, the global Tamiflu (Oseltamivir Phosphate) market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
North America accounted for major share of the global Tamiflu (Oseltamivir Phosphate) market in 2018. Higher prevalence of influenza, presence of major companies in the region, and better influenza surveillance for reporting on weekly basis are some of the major factors responsible for the growth of North America Tamiflu (Oseltamivir Phosphate) market.
The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process
Major Players
The report concludes with company profiles section that includes key information about the major players in the market
Key players analyzed in this report are
- F.Hoffmann-La Roche Ltd.
- NATCO Pharma Limited
- Tea Pharmaceutical Industries Ltd.
- LUPIN Limited
- Amneal Pharmaceuticals LLC
- Zydus Cadila
- Sun Pharmaceutical Industries Ltd.
- Alembic Pharmaceuticals Limited
- Mylan N.V.
- Hetero Group
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Tamiflu (Oseltamivir Phosphate) Market Report
- What is the sales/revenue generated by each drug type, dosage form segments of the Tamiflu (Oseltamivir Phosphate) market across all regions during the forecast period?
- What are the opportunities in the global Tamiflu (Oseltamivir Phosphate) market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which region is likely to expand at the fastest CAGR during the forecast period?
- Which Tamiflu (Oseltamivir Phosphate) indication and distribution channel segments are expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
- What is the market share or position of different companies operating in the global market in 2018?
Tamiflu (Oseltamivir Phosphate) Market – Segmentation
Drug Type
- Branded
- Generic
Dosage Form
- Capsule
- Suspension
Indication
- Influenza A
- Influenza B
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111898/2900
